Back to top
more

Cellectis (CLLS)

(Delayed Data from NSDQ)

$1.77 USD

1.77
124,026

-0.01 (-0.56%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $1.75 -0.02 (-1.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

ImmunoGen Posts Wider-than-Expected Loss; Sales Down Y/Y

ImmunoGen, Inc. (IMGN) reported a loss of 39 cents per share (excluding restructuring charge) in the three month transition period ended Dec 31, marginally wider than both the Zacks Consensus Estimate and the year-ago loss of 38 cents.

    Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.

    Valeant Pharmaceuticals (VRX) recently announced that the the FDA has approved its Biologic License Application (BLA) for Siliq (brodalumab) injection the treatment of moderate-to-severe plaque psoriasis in adult patients.

      Acorda (ACOR) Reports Narrower-than-Expected Loss in Q4

      Acorda Therapeutics, Inc. (ACOR) reported loss of 7 cents per share in the fourth quarter of 2016 (including the impact of stock-based compensation expenses), narrower than the Zacks Consensus Estimate of a loss of 18 cents.

        Ascendis (ASND) Catches Eye: Stock Gains 7.2% in Session

        Ascendis Pharma A/S (ASND) moved big last session, as its shares rose over 7% on the day.

          Abeona Therapeutics (ABEO) Catches Eye: Stock Jumps 5.8%

          Abeona Therapeutics Inc.(ABEO) was a big mover last session, as the company saw its shares rise nearly 6% on the day.

            Acorda (ACOR) Catches Eye: Stock Gains 20.8% in Session

            Acorda Therapeutics, Inc. (ACOR) moved big last session, as its shares rose almost 21% on the day.

              Will Cellectis (CLLS) Continue to Surge Higher?

              As of late, it has definitely been a great time to be an investor in Cellectis SA (CLLS).

                The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                The Zacks Analyst Blog Highlights: Celgene, Cellectis S.A., Exelixis, Exact Sciences and Sunesis Pharmaceuticals

                  Cellectis (CLLS) Shows Strength: Stock Moves 9.1% Higher

                  Cellectis S.A. (CLLS) shares rose over 9% in the last trading session.

                    Why Cellectis (CLLS) Stock Might be a Great Pick

                    Cellectis (CLLS) in the Medical-Biomedical/Genetics space is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.